Hematology

Treatment will be available for clinical trials in patients with certain types of leukemia and non-Hodgkin lymphomas later this year.

The FDA is considering approval for a liquid bendamustine hydrochloride rapid infusion product.

Longer telomeres gives cancer cells a survival advantage.

Ibrutinib found to control Waldenstrom's Macroglobulinemia in 95% of patients.

Enzyme blocker reduces growth of intestinal tumors.

Private insurers and Medicare patients can pay up to 43 times less than the uninsured.

Drug could eventually also treat prostate cancer.

Less toxic drug class combined with fasting may kill breast, lung, and colon cancer cells equally well.

Engineered protein improves survival rates in aggressive leukemia.

Compounds that prevent protein aggregation may lead to therapy for conditions such as cancer and diabetes.

Kyprolis has already been approved for patients who failed at least 2 previous therapies.

The FDA has granted priority review status to Amgen's supplemental New Drug Application for its carfilzomib (Kyprolis) cancer therapy.

Researchers believe drug will lead to ‘new paradigm' in leukemia therapy.

Scalp cooling technology seeks to ensure hair retention in most instances.

Costs have risen 120% in aggregate since 1995.

Study finds depression in African American cancer patients has gone under-recognized.

Compound can monitor biochemical processes involved with protein kinases.

Celgene today announced that the FDA has granted an expanded use approval for its multiple myeloma drug, lenalidomide (Revlimid).

Study examines how side effects from commonly used antibiotics effect mitochondria of cancer cells.

In 2014, the FDA approved notable new therapies for the treatment of cancer, bleeding disorders, inflammatory conditions, cystic fibrosis, pulmonary fibrosis, HIV, hepatitis C, multiple sclerosis, angioedema, and other conditions.

Efficacy and safety demonstrated in models of aggressive leukemia.

Expanded indication would include patients with relapsed multiple myeloma who received prior therapy.

Phase 3 trial for polycythemia vera drug significantly improved hematocrit control without the need for phlebotomy.

Chimeric antigen receptor may be able to treat a number of cancer types.

Pharmacists can play a vital role by finding financial aid through foundations and co-pay programs.